Updates on Legal Developments in the EU Life Sciences Industry
Originally published as Covington E-Alert on October 9, 2009
May a pharmaceutical company charge its wholesalers one price for products to be resold under the national healthcare reimbursement rules, and another, higher price for products to be resold in another EU member state? This was the question addressed by the European Court of Justice (ECJ)…
Article originally published in Competition Law Insight on November 25, 2008
May a dominant pharmaceutical company refuse to supply in full the orders it receives from a wholesaler in an EU member state in order to limit parallel trade in its products in the European Union? This was the question addressed by the European Court …
Article originally published in PLC Cross-border Life Sciences Handbook, 2007/08
Apart from patent disputes linked to generic entry, perhaps no issue has spawned more litigation in the European pharmaceutical sector than parallel trade. At the root of the problem are price differences among member states for pharmaceutical products which are caused by national price controls.…
Originally published as Covington Life Sciences Alert on June 1st, 2005
May a dominant pharmaceutical company refuse to supply in full the orders it receives from a wholesaler in an EU country in order to limit parallel trade in its products in the European Union? This was the question put to the European Court of…
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website. To exercise your right to opt-out of the sale or sharing of your personal information for targeted advertising purposes, click “reject.” Privacy Policy
